Violation Tracker Parent Company Summary
Parent Company Name:
Sanofi
Ownership Structure:
publicly traded
Headquartered in:
France
Major Industry:
pharmaceuticals
Specific Industry:
pharmaceuticals
Penalty total since 2000:
$544,996,233
Number of records:
11
| Top 10 Primary Offense Types | Penalty Total | Number of Records |
|---|---|---|
| False Claims Act | $436,648,194 | 5 |
| drug or medical equipment safety violation | $55,781,039 | 2 |
| Foreign Corrupt Practices Act | $25,200,000 | 1 |
| employment discrimination | $15,360,000 | 1 |
| price-fixing or anti-competitive practices | $12,000,000 | 1 |
| workplace safety or health violation | $7,000 | 1 |
Notes:
Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the Update Log, which may vary from what was the case when a violation occurred. The penalty dollar total above may be adjusted to account for the fact that the list of entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. Duplicate penalty amounts are marked with an asterisk in the list below.
Associated Names:
AVENTIS PHARMACEUTICAL; AVENTIS PHARMACEUTICALS; GENZYME; Hoechst AG; ROUSSEL UCLAF SA; SANOFI; Sanofi-Aventis U.S. LLC
Links:
For more details on misconduct by this company, see its entry in the Project On Government Oversight's Federal Contractor Misconduct Database.
For a summary of this company's federal contracts, see its page on Fedspending.
Subsidy Tracker data on financial assistance to this company by federal, state and local government agencies can be found here.
Individual Penalty Records:
Click on the company or penalty amount for more information on each case.
Download results as 
or XML
or XML
| Company | Primary Offense Type | Year | Agency |
Penalty Amount |
|---|---|---|---|---|
| Aventis Pharmaceuticals Inc. | False Claims Act | 2007 | DOJ_CIVIL | $190,000,000 |
| Sanofi-Aventis U.S. Inc. | False Claims Act | 2012 | DOJ_CIVIL | $109,000,000 |
| Aventis Pharmaceutical Inc. | False Claims Act | 2009 | DOJ_CIVIL | $95,500,000 |
| Genzyme Corporation | drug or medical equipment safety violation | 2015 | FDA | $32,587,439 |
| Sanofi | Foreign Corrupt Practices Act | 2018 | SEC | $25,200,000 |
| Roussel Uclaf S.A. | drug or medical equipment safety violation | 2001 | USAO | $23,193,600 |
| Genzyme Corp. | False Claims Act | 2013 | DOJ_CIVIL | $22,280,000 |
| Sanofi-Pasteur | False Claims Act | 2017 | DOJ_CIVIL | $19,868,194 |
| Sanofi-Aventis U.S. LLC | employment discrimination | 2010 | private lawsuit-federal | $15,360,000 |
| Hoechst AG | price-fixing or anti-competitive practices | 2003 | DOJ_ANTITRUST | $12,000,000 |
| SANOFI PASTEUR INC. | workplace safety or health violation | 2014 | OSHA | $7,000 |
Download results as or XML
or XML
